While antibiotics and vaccines have contributed to the management of many microbial diseases, viruses present an especially difficult medical challenge. The molecular characteristics of viruses and their rapid mutation rates make them a moving target for both drug therapy and vaccines. The time required for development and approval of new antivirals and vaccines is lengthy and is in sharp contrast to the viruses’ ability to rapidly mutate to less controllable forms. As a result, very few effective and safe antivirals exist and the health and economic impacts of diseases of viral etiology could increase significantly in the coming decades.

Intrucept’s broad-spectrum antivirals have the potential for managing diseases caused by a wide variety of viral pathogens. Just as important, the Company’s lead APIs do not bind human serum proteins and have shown no cellular or organ toxicity in vitro or in vivo at concentrations greatly exceeding those required for therapeutic effect. This is significant because the ability to use therapeutic proteins in lower doses while maintaining efficacy could lead to higher safety margins (including lower potential immunogenicity), a lower cost of therapy, and thus the potential to penetrate markets more efficiently.

Through collaborative partnerships, Intrucept is developing novel formulations for microbicides comprising the Company’s lead molecules. Microbicides often represent the only effective mode of protection against HIV and genital herpes for women in developing countries. The high potency and tolerability of our APIs and the low manufacturing cost for final dosage forms support our R&D in this price-sensitive market. Animal health and veterinary medicine are also markets defined by price constraints, and the Company has on-going exploratory programs to develop products for these end uses. In addition, exploratory programs are in place to exploit biodefense and industrial applications of the Company’s technologies.